

Fig. 1

44.9%), followed by NDM (1822, 35.5%), IMP (313, 6.1%), VIM (207, 4.0%), NDM+OXA-48-like (205, 4.0%), and KPC (196, 3.8%). The first detection of a CPE with 2 distinct enzymes occurred in 2012 (OXA-48-like and NDM) and since then 235 co-detections have been identified; 233 related to OXA-48-like with another gene. **Conclusion:** The first CPE isolate in London was identified in 2003, a *Klebsiella* spp with a VIM enzyme. The number of isolates submitted to the national reference laboratory has continued to increase year on year. VIM and NDM carbapenemases predominated in the early years, because of their association with several outbreaks; these have now been overwhelmed by OXA-48-like detections and outbreaks. The increasing numbers of CPE with a combination of a metallo- and a non-metallo carbapenemase increases the therapeutic challenges to treat infected patients. Bacteremia caused by CPE remains rare, suggesting that infection prevention and control efforts are having some impact. However, as colonization prevalence increases, the number of clinical infections will rise in the future unless control measures to limit transmission and spread are improved.

Funding: None

Disclosures: None

Doi:[10.1017/ice.2020.477](https://doi.org/10.1017/ice.2020.477)

Presentation Type:

Distinguished Oral

Clinical Metrics for a Large Healthcare System's Antimicrobial Management Program

Hayley Burgess, HCA Healthcare; Joan Kramer, HCA Healthcare; Elizabeth Hofammann, HCA Healthcare; Mandelin Cooper, HCA Healthcare

Background: Clinical metrics and outcomes for evaluation of antimicrobial management programs (AMP) are challenging and inconsistent throughout the United States. Here, we present the results of the development of clinical metrics to measure and trend AMP outcomes within 161 acute-care facilities affiliated with a large healthcare system. **Methods:** Key AMP metrics were implemented in 2018 using 2017 as baseline: use of fluoroquinolones in UTIs, dosing of vancomycin, de-escalation, and intravenous (IV)-to-oral conversion of targeted drugs. **Fluoroquinolone (FQ) and UTI metric** evaluated all inpatients who received at least 1 dose of a FQ based on barcoded medication administration (BCMA) data and urinary tract infections were based on cystitis ICD-10

coding. **Vancomycin dosing metric** evaluated inpatient vancomycin troughs within therapeutic range during the admission. **De-escalation metric** evaluated for patients on a broad-spectrum antibiotic with a positive culture and sensitivity to narrower antibiotics. The **IV-to-oral ratio** was used to monitor targeted medications. Nonantimicrobial medications appropriate for IV-to-oral conversion were included in the ratio. Goals were established for each metric using the 75th percentile and ranges for "at goal," "close to goal," and "not at goal" were established using green-yellow-red color coding. Metrics were monitored via a systemwide dashboard that included all affiliated facilities. Data were shared monthly to key stakeholders including physicians, pharmacists, and senior leadership. **Results:** From 2017 to the third quarter of 2019, the FQ and UTI metric decreased 55%. This reduction in the FQ usage in UTI metric correlated with a reduction of 26.7 days of therapy (DOT) per 1,000 days present for FQ and a 50% reduction in FQ DOT for all affiliated facilities. The vancomycin dosing metric improved 2.9% from 75.2% of patients to 78.1% of patients with at least 1 vancomycin trough within range during the admission, which represents ~2,000 more patients with dosing in the target range over baseline. The de-escalation metric improved by 7% overall from 2018 to the third quarter of 2019, which translates to ~1,600 more patients with therapy de-escalated. The IV-to-oral ratio metric improved 5.5%, which means that ~180,000 more oral dosages were administered. **Conclusions:** Implementing AMP program clinical metrics in a large health system positively influenced antimicrobial medication therapy management for patients. Monitoring of process metrics should be considered for all AMP programs to advance antibiotic stewardship.

Funding: None

Disclosures: None

Doi:[10.1017/ice.2020.478](https://doi.org/10.1017/ice.2020.478)

Presentation Type:

Distinguished Oral

Decreased Hospitalizations and Costs From Infection in Sixteen Nursing Homes in the SHIELD OC Regional Decolonization Initiative

Gabrielle M. Gussin, University of California, Irvine; James A. McKinnell, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA; Raveena D. Singh, University of California, Irvine School of Medicine; Ken Kleinman, University

Outcomes per Medicaid Member per Quarter




Fig. 1.

of Massachusetts, Amherst Loren Miller, Harbor-UCLA Medical Center; Raheeb Saavedra, University of California Irvine School of Medicine; Lauren Heim, University of California, Irvine; Marlene Estevez, University of California, Irvine; Tabitha D. Catuna, University of California, Irvine; Eunjung Lee, University of California, Irvine; Thomas Tjoa, University of California at Irvine; Rachel Slayton, Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion; Nimalie Stone, Centers for Disease Control and Prevention; John Jernigan, Centers for Disease Control and Prevention; Matthew Zahn, Orange County Health Care Agency; Lynn Janssen, California Dept. of Public Health; Shruti K Gohil, University of California, Irvine; Steven Tam; Philip Alan Robinson, Hoag Hospital; Steven Park, University of California, Irvine; Robert Weinstein, Rush University Medical Center; Mary Hayden, Rush University Medical Center; Cassiana E. Bittencourt, University of California, Irvine; Ellena M. Peterson, University of California, Irvine
Susan Huang, University of California Irvine School of Medicine

Background: Shared Healthcare Intervention to Eliminate Life-threatening Dissemination of MDROs in Orange County, California (SHIELD OC) was a CDC-funded regional decolonization intervention from April 2017 through July 2019 involving 38 hospitals, nursing homes (NHs), and long-term acute-care hospitals (LTACHs) to reduce MDROs. Decolonization in NH and LTACHs consisted of universal antiseptic bathing with chlorhexidine (CHG) for routine bathing and showering plus nasal iodophor decolonization (Monday through Friday, twice daily every other week). Hospitals used universal CHG in ICUs and provided daily CHG and nasal iodophor to patients in contact precautions. We sought to evaluate whether decolonization reduced hospitalization and associated healthcare costs due to infections among residents of NHs participating in SHIELD compared to nonparticipating NHs. **Methods:** Medicaid insurer data covering NH residents in Orange County were used to calculate hospitalization rates due to a primary diagnosis of infection (counts per member quarter), hospital bed days/member-quarter, and expenditures/member quarter from the fourth quarter of 2015 to the second quarter of 2019. We used a time-series design and a segmented regression analysis to evaluate changes attributable to the SHIELD OC intervention among participating and nonparticipating NHs. **Results:** Across the SHIELD OC intervention period, intervention

NHs experienced a 44% decrease in hospitalization rates, a 43% decrease in hospital bed days, and a 53% decrease in Medicaid expenditures when comparing the last quarter of the intervention to the baseline period (Fig. 1). These data translated to a significant downward slope, with a reduction of 4% per quarter in hospital admissions due to infection ($P < .001$), a reduction of 7% per quarter in hospitalization days due to infection ($P < .001$), and a reduction of 9% per quarter in Medicaid expenditures ($P = .019$) per NH resident. **Conclusions:** The universal CHG bathing and nasal decolonization intervention adopted by NHs in the SHIELD OC collaborative resulted in large, meaningful reductions in hospitalization events, hospitalization days, and healthcare expenditures among Medicaid-insured NH residents. The findings led CalOptima, the Medicaid provider in Orange County, California, to launch an NH incentive program that provides dedicated training and covers the cost of CHG and nasal iodophor for OC NHs that enroll.

Funding: None

Disclosures: Gabrielle M. Gussin, University of California, Irvine, Stryker (Sage Products): Conducting studies in which contributed antiseptic product is provided to participating hospitals and nursing homes. Clorox: Conducting studies in which contributed antiseptic product is provided to participating hospitals and nursing homes. Medline: Conducting studies in which contributed antiseptic product is provided to participating hospitals and nursing homes. Xttrium: Conducting studies in which contributed antiseptic product is provided to participating hospitals and nursing homes.

Doi:10.1017/ice.2020.479

Presentation Type:

Distinguished Oral

Implementation of the Comprehensive Unit-Based Safety Program to Improve Hand Hygiene in Four NICUs in Pune, India

Julia Johnson, Johns Hopkins University; Asad Latif, Anesthesia and Critical Care Medicine, Johns Hopkins University; Bharat Randive, Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site; Abhay Kadam, Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site; Uday Rajput, Pediatrics, Byramjee Jeejeebhoy Government Medical College; Aarti Kinikar, Pediatrics, Byramjee Jeejeebhoy Government Medical College; Nandini Malshe, Neonatology, Bharati